RT Journal Article
SR Electronic
T1 Targeting myeloid-derived suppressor cells for cancer therapy
JF Cancer Biology & Medicine
JO Cancer Biol Med
FD China Anti-Cancer Association
SP 992
OP 1009
DO 10.20892/j.issn.2095-3941.2020.0806
VO 18
IS 4
A1 Hongchao Tang
A1 Hao Li
A1 Zhijun Sun
YR 2021
UL http://www.cancerbiomed.org/content/18/4/992.abstract
AB The emergence and clinical application of immunotherapy is considered a promising breakthrough in cancer treatment. According to the literature, immune checkpoint blockade (ICB) has achieved positive clinical responses in different cancer types, although its clinical efficacy remains limited in some patients. The main obstacle to inducing effective antitumor immune responses with ICB is the development of an immunosuppressive tumor microenvironment. Myeloid-derived suppressor cells (MDSCs), as major immune cells that mediate tumor immunosuppression, are intimately involved in regulating the resistance of cancer patients to ICB therapy and to clinical cancer staging and prognosis. Therefore, a combined treatment strategy using MDSC inhibitors and ICB has been proposed and continually improved. This article discusses the immunosuppressive mechanism, clinical significance, and visualization methods of MDSCs. More importantly, it describes current research progress on compounds targeting MDSCs to enhance the antitumor efficacy of ICB.